Dr. Cipto Mangunkusumo Hospital Treats Indonesia's First Patient on Varian's Halcyon System
PALO ALTO, California and SINGAPORE, July 1, 2020 /PRNewswire/ -- Dr. Cipto Mangunkusumo Hospital, Jakarta has become the first hospital in Indonesia to treat patients using Varian's Halcyon™ system. The first patient, a 14 year old female, was treated for Hodgkin lymphoma.
By 2040, more than 575,000 cancer cases are predicted to be reported in Indonesia. This signifies nearly a two-thirds increase from the 350,000 cases that were estimated in 2018.[1]
Prof. Soehartati A. Gondhowiardjo, MD, PhD, Senior Radiation Oncologist, Cipto Mangunkusumo National General Hospital, said: "We are proud to be the first hospital in Indonesia to be able to offer the high quality of care, operational excellence, and fully image-guided radiation therapy to our patients. Compared to our existing Varian linear accelerator, Halcyon is much easier and intuitive to operate. We are delighted to be at the forefront of bringing this innovation to the people of Indonesia."
Halcyon features a streamlined workflow that only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon offers expedited commissioning, requires less shielding than traditional systems, can fit in a majority of the existing small vaults, and can be installed in two weeks or less. The system is well suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.
Kevin Lo, managing director, Southeast Asia, Korea, Hong Kong & Macau Region, Varian Asia Pacific, said: "We are delighted to partner with Dr. Cipto Mangunkusumo Hospital to bring the first Halcyon radiotherapy system to Indonesia. We strive to bring advanced technology to cancer patients across all communities. Cancer patients in Indonesia now have access to cutting edge technology in their fight against cancer."
About Varian
At Varian (NYSE: VAR), we envision a world without fear of cancer. For more than 70 years, we have developed, built and delivered innovative cancer care technologies and solutions for our clinical partners around the globe to help them treat millions of patients each year. With an Intelligent Cancer Care approach, we are harnessing advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care. Our 10,000 employees across 70 locations keep the patient and our clinical partners at the center of our thinking as we power new victories in cancer care. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
[1] International Agency for Research on Cancer, Cancer Tomorrow. Accessed on 16 March 2020: https://gco.iarc.fr/tomorrow/graphic-isotype?type=0&population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0
Press Contact
Christine Hogseth-Gill
Head of Public Affairs, Asia Pacific and Japan
+65 93881352
christine.hogseth-gill@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
SOURCE Varian Medical Systems
